Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BI409306 Film-coated Tablets Given Orally Qd for 14 Days in Patients with Mild-to-moderate Schizophrenia

被引：0

作者：

Brown, David ^{[1
]}

Daniels, Kristen ^{[2
]}

Zhang, Shu ^{[3
]}

Pichereau, Solen ^{[4
]}

Sand, Michael ^{[5
]}

机构：

[1] Community Clin Res Inc, Off, Austin, TX USA

[2] Boehringer Ingelheim Pharmaceut Inc, Coclin Trial Mgmt E 3, BIP US, Ridgefield, CT 06877 USA

[3] Boehringer Ingelheim Pharmaceut Inc, BDM Clin Biostat GRP 2, BIP US, Ridgefield, CT 06877 USA

[4] Novartis, Non Clin DMPK, Basel, Switzerland

[5] Boehringer Ingelheim Pharmaceut Inc, Gen Med, Clin Res, BIP US, Ridgefield, CT 06877 USA

来源：

关键词：

PDE9; inhibitor; schizophrenia; cognition; BI; 40930; pharmacokinetics;

D O I：

暂无

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

519

引用

页数：1